Trial site
University of Cincinnati Cancer Center
- 13running trials
- 4closed trials
The trials here
What the 17 trials at this site are about, from their registry records.
- Conditions
- Colorectal cancer3 trials
- Lung cancer3 trials
- Bladder cancer2 trials
- Endometrial cancer2 trials
- Gastric and oesophageal cancer2 trials
- Head and neck cancer2 trials
- Melanoma2 trials
- Pancreatic cancer2 trials
- Acute myeloid leukaemia1 trial
- Amyloidosis1 trial
- Cervical cancer1 trial
- Multiple myeloma1 trial
- and 1 more
- Phase
- Phase 1/27 trials
- Phase 36 trials
- Phase 22 trials
- Phase 11 trial
- Phase 2/31 trial
- Status
- Recruiting8 trials
- Active, not recruiting5 trials
- Terminated3 trials
- Completed1 trial
- Lead sponsor
- Acrivon Therapeutics1 trial
- Adlai Nortye Biopharma Co., Ltd.1 trial
- BioNTech SE1 trial
- CG Oncology, Inc.1 trial
- Delta-Fly Pharma, Inc.1 trial
- and 12 more
Running trials
Recruiting
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Recruiting
A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
Recruiting
Recruiting
Recruiting
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Recruiting
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
Active, not recruiting
Active, not recruiting
Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis
Recruiting
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
Recruiting
Active, not recruiting
Recruiting
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
Active, not recruiting
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Colorectal cancer2 recruiting
- Lung cancer2 recruiting
- Melanoma2 recruiting
- Bladder cancer1 recruiting
- Endometrial cancer1 recruiting
- Pancreatic cancer1 recruiting
Closed trials
Site data: ClinicalTrials.govUpdated 18 Nov 2026